Evidence map›Paper›PMID 35530725›Full record

ReviewGene reports2022

Therapeutic approaches and vaccination in fighting COVID-19 infections: A review.

Setare Adibzadeh, Shahin Amiri, Giti Esmail Nia, Maryam Rezakhani Taleghani, Zahra Kohanrooz Bijarpas, Neda Maserat, Amirhosein Maali, Mehdi Azad, Abbas Behzad-Behbahani

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Gene reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Setare AdibzadehMedical Biotechnology Department, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran.
Shahin AmiriMedical Biotechnology Department, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran.
Giti Esmail NiaFaculty of Allied Medicine, Cellular and Molecular Research Centre, Iran University of Medical Science, Tehran, Iran.
Maryam Rezakhani TaleghaniBiotechnology Research Institute of Industry and Environment, National Institute of Genetic Engineering and Biotechnology, Tehran, Iran.
Zahra Kohanrooz BijarpasDepartment of Biology, Parand Branch, Islamic Azad University, Tehran, Iran.
Neda MaseratDepartment of Biology, Sistan and Balouchestan University, Zahedan, Iran.
Amirhosein MaaliDepartment of Immunology, Pasteur Institute of Iran, Tehran, Iran.
Mehdi AzadDepartment of Medical Laboratory Sciences, Faculty of Allied Medicine, Qazvin University of Medical Sciences, Qazvin, Iran.
Abbas Behzad-BehbahaniDiagnostic Laboratory Sciences and Technology Research Center, School of Paramedical Sciences, Shiraz University of Medical Sciences, Shiraz, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Coronavirus disease 2019 (COVID-19) is a remarkably contagious and pathogenic viral infection arising from the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which first appeared in Wuhan, China. For the time being, COVID-19 is not treated with a specific therapy. The Food and Drug Administration (FDA) has approved Remdesivir as the first drug to treat COVID-19. However, many other therapeutic approaches are being investigated as possible treatments for COVID-19. As part of this review, we discussed the development of various drugs, their mechanism of action, and how they might be applied to different cases of COVID-19 patients. Furthermore, this review highlights an update in the emergence of new prophylactic or therapeutic vaccines against COVID-19. In addition to FDA or The World Health Organization (WHO) approved vaccines, we intended to incorporate the latest published data from phase III trials about different COVID-19 vaccines and provide clinical data released on the networks or peer-review journals.

Indexed as

ACE2, Angiotensin-converting enzyme 2Antiviral agentsArb, ArbidolARDS, Acute respiratory distress syndromeCOVID-19COVID-19, Coronavirus disease 2019ER, Endoplasmic reticulumERGIC, Endoplasmic reticulum Golgi intermediate compartmentFDA, Food and Drug AdministrationgRNA, Genomic RNAHIV, Human immunodeficiency virusmAbs, Monoclonal antibodiesMERS-CoV, The Middle East respiratory syndrome 20 coronavirusORFs, Open reading framesPandemicsPneumoniaRBD, Receptor binding domainRdRp, RNA-dependent RNA polymeraseRTC, Replicase transcriptase complexSARS-CoV-2SARS-CoV-2, Severe acute respiratory syndrome of coronavirus 2sgRNA, Subgenomic RNAVaccinesVLPs, Virus-like particlesWHO, World Health OrganizationWMT, Washed microbiota transplantation

Identifiers

PMID35530725
PMCPMC9066810

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.